Azenosertib

Phase 3Small molecule

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib is one of 102 small molecule programs targeting Osteosarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerRecruiting

Primary Peritoneal CancerRecruiting

OsteosarcomaPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 3

Recruiting

Primary Peritoneal CancerPhase 2

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

Byetta

AstraZeneca

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Primary Peritoneal Cancer

NCT05128825

Q3 2027

Phase 1Recruiting

Other Solid Tumors

NCT06364410

Q1 2028

Phase 2Recruiting

Serous Carcinoma

NCT06369155

Phase 1Recruiting

Pancreatic Cancer

NCT04005690

Q3 2029

Phase 1/2Active, not recruiting

Pembrolizumab

NCT06351332

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT05198804·117 enrolled

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 3·NCT07546500·420 enrolled

Serous Carcinoma2 trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Recruiting·—·Phase 2·NCT06369155·25 enrolled

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT04814108·92 enrolled

Pembrolizumab1 trial

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Active, not recruiting·FFilipa Lynce, MD·Phase 1/2·NCT06351332·78 enrolled

Solid Tumors1 trial

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1·NCT04158336·274 enrolled

Other Solid Tumors1 trial

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06364410·48 enrolled

3 more indications

Pancreatic Cancer1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04005690·90 enrolled

Osteosarcoma1 trial

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT04833582·31 enrolled

Primary Peritoneal Cancer1 trial

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT05128825·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Azenosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azenosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azenosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Ovarian Cancer2 trials

Serous Carcinoma2 trials

Pembrolizumab1 trial

Solid Tumors1 trial

Other Solid Tumors1 trial

Pancreatic Cancer1 trial

Osteosarcoma1 trial

Primary Peritoneal Cancer1 trial

References

Drug Info

Quick Facts

Related News